Ian MacLachlan

11.7k total citations · 2 hit papers
49 papers, 6.7k citations indexed

About

Ian MacLachlan is a scholar working on Molecular Biology, Genetics and Cancer Research. According to data from OpenAlex, Ian MacLachlan has authored 49 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 14 papers in Genetics and 10 papers in Cancer Research. Recurrent topics in Ian MacLachlan's work include RNA Interference and Gene Delivery (31 papers), Advanced biosensing and bioanalysis techniques (12 papers) and Virus-based gene therapy research (10 papers). Ian MacLachlan is often cited by papers focused on RNA Interference and Gene Delivery (31 papers), Advanced biosensing and bioanalysis techniques (12 papers) and Virus-based gene therapy research (10 papers). Ian MacLachlan collaborates with scholars based in United States, Canada and Austria. Ian MacLachlan's co-authors include Adam D. Judge, Kevin McClintock, Marjorie Robbins, Lorne Palmer, Vandana Sood, James Heyes, Dianne Fang, Amy C. H. Lee, Ellen Ambegia and K. Helen Bremner and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Ian MacLachlan

49 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

2005 957 citations Adam D. Judge, Vandana Sood et al. Nature Biotechnology profile →
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

2005 908 citations Dylan Morrissey, Jennifer A. Lockridge et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ian MacLachlan United States	30	5.5k	1.4k	1.1k	1.1k	776	49	6.7k
Adam D. Judge United States	18	3.8k 0.7×	1.3k 0.9×	584 0.5×	1.1k 1.0×	483 0.6×	25	4.9k
Premlata Shankar United States	35	4.9k 0.9×	1.2k 0.8×	1.2k 1.1×	2.3k 2.2×	533 0.7×	68	7.6k
Jens Harborth Germany	16	8.7k 1.6×	1.6k 1.1×	1.5k 1.3×	855 0.8×	237 0.3×	24	9.9k
Sayda M. Elbashir United States	16	12.4k 2.3×	2.7k 1.9×	2.1k 1.9×	1.3k 1.2×	542 0.7×	26	14.2k
Barbara L. Mui United States	27	5.2k 1.0×	360 0.2×	1.0k 0.9×	1.3k 1.2×	1.2k 1.5×	36	6.5k
N. Manjunath United States	36	3.2k 0.6×	868 0.6×	692 0.6×	3.2k 3.0×	474 0.6×	67	6.8k
Hong M. Moulton United States	43	4.1k 0.7×	272 0.2×	1.0k 0.9×	578 0.5×	985 1.3×	83	5.5k
Tal Zaks United States	27	4.2k 0.8×	535 0.4×	748 0.7×	1.9k 1.7×	1.2k 1.5×	51	6.9k
Sang‐Kyung Lee South Korea	23	3.3k 0.6×	565 0.4×	824 0.7×	505 0.5×	188 0.2×	49	4.1k
Ying K. Tam United States	45	6.5k 1.2×	517 0.4×	1.2k 1.1×	2.5k 2.3×	1.8k 2.3×	107	9.3k

Countries citing papers authored by Ian MacLachlan

Since Specialization

Citations

This map shows the geographic impact of Ian MacLachlan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian MacLachlan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian MacLachlan more than expected).

Fields of papers citing papers by Ian MacLachlan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian MacLachlan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian MacLachlan. The network helps show where Ian MacLachlan may publish in the future.

Co-authorship network of co-authors of Ian MacLachlan

This figure shows the co-authorship network connecting the top 25 collaborators of Ian MacLachlan. A scholar is included among the top collaborators of Ian MacLachlan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian MacLachlan. Ian MacLachlan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahony, Colin, Ian MacLachlan, Brandon M. Lind, et al.. (2019). Evaluating genomic data for management of local adaptation in a changing climate: A lodgepole pine case study. Evolutionary Applications. 13(1). 116–131. 63 indexed citations

Thi, Emily P., Chad E. Mire, Amy C. H. Lee, et al.. (2015). Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature. 521(7552). 362–365. 190 indexed citations

Lee, Yun-Han, Daekwan Seo, Kyung‐Ju Choi, et al.. (2014). Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2. Cancer Research. 74(17). 4752–4761. 77 indexed citations

Ursic-Bedoya, Raùl, Chad E. Mire, Marjorie Robbins, et al.. (2013). Protection Against Lethal Marburg Virus Infection Mediated by Lipid Encapsulated Small Interfering RNA. The Journal of Infectious Diseases. 209(4). 562–570. 44 indexed citations

Ma, Han, Anne Dallas, Heini Ilves, et al.. (2013). Formulated Minimal-Length Synthetic Small Hairpin RNAs Are Potent Inhibitors of Hepatitis C Virus in Mice With Humanized Livers. Gastroenterology. 146(1). 63–66.e5. 21 indexed citations

Dallas, Anne, Heini Ilves, Joshua Shorenstein, et al.. (2013). Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice. Molecular Therapy — Nucleic Acids. 2. e123–e123. 14 indexed citations

Lee, Young Ho, Andrew Judge, Dong‐Chul Seo, et al.. (2011). Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene. 30(40). 4175–4184. 64 indexed citations

Lee, Yun-Han, Jesper B. Andersen, Ho‐Taek Song, et al.. (2010). Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma. Cancer Research. 70(21). 8264–8269. 60 indexed citations

Geisbert, Thomas W., Marjorie Robbins, Joan B. Geisbert, et al.. (2010). Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. The Lancet. 375(9729). 1896–1905. 342 indexed citations

10.

Judge, Adam D., Marjorie Robbins, Iran Tavakoli, et al.. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. Journal of Clinical Investigation. 119(3). 661–673. 273 indexed citations

11.

Geisbert, Thomas W., Lisa E. Hensley, Elliott Kagan, et al.. (2006). Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference. The Journal of Infectious Diseases. 193(12). 1650–1657. 181 indexed citations

12.

Ambegia, Ellen, Steven M. Ansell, P.R. Cullis, et al.. (2005). Stabilized plasmid–lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1669(2). 155–163. 171 indexed citations

13.

Judge, Adam D., Kevin McClintock, Janet R. Phelps, & Ian MacLachlan. (2005). Hypersensitivity and Loss of Disease Site Targeting Caused by Antibody Responses to PEGylated Liposomes. Molecular Therapy. 13(2). 328–337. 225 indexed citations

14.

Judge, Adam D., et al.. (2005). Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo. Molecular Therapy. 13(3). 494–505. 437 indexed citations

15.

Morrissey, Dylan, Jennifer A. Lockridge, Karin S. Blanchard, et al.. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology. 23(8). 1002–1007. 908 indexed citations breakdown →

16.

Jeffs, Lloyd B., et al.. (2005). A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA. Pharmaceutical Research. 22(3). 362–372. 257 indexed citations

17.

Finn, Jonathan D., et al.. (2004). An enhanced autogene-based dual-promoter cytoplasmic expression system yields increased gene expression. Gene Therapy. 11(3). 276–283. 20 indexed citations

18.

Pampinella, Francesca, et al.. (2002). Analysis of Differential Lipofection Efficiency in Primary and Established Myoblasts. Molecular Therapy. 5(2). 161–169. 34 indexed citations

19.

Fenske, David B., Ian MacLachlan, & Pieter R. Cullis. (2002). [3] Stabilized plasmid-lipid particles: A systemic gene therapy vector. Methods in enzymology on CD-ROM/Methods in enzymology. 346. 36–71. 56 indexed citations

20.

Tam, Pat, et al.. (1999). Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene Therapy. 6(3). 403–411. 207 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact